Invo Bioscience Launches INVOcell and IVC in Malaysia’s Leading Fertility Centre

September 2022

Invo Bioscience Inc, a US-headquartered medical device firm specializing in commercial-stage fertility, has expanded the worldwide access of its INVOcell ® medical device and the intravaginal culture (IVC) procedure at the Hospital Canselor Tuanku Muhriz (HCTM). HCTM is located in Kuala Lumpur, Malaysia.

HCTM, formally known as Hospital Universiti Kebangsaan Malaysia (HUKM), is one of the five university hospitals in Malaysia with the highest volume of fertility centers. Invo Bioscience will bring in INVOcell ® medical device and IVC procedure at the Advanced Reproductive Centre of HCTM. According to data given at the Obstetrical and Gynecological Society of Malaysia (OGSM), Invo Bioscience has successfully completed the first IVC case in Malaysia and earned the prize as a new and unique reproductive treatment.

Steve Shum, CEO of Invo Bioscience, stated that INVOcell would soon begin official commercialization at HCTM. The hospital will offer IVC both in their public and private sectors to complete a number of cycles by end of 2022. The firm is also working with local partners to build an INVO Center in their facility and expand the greater access to innovative advanced fertility treatment in the local community.

(Sources: Invo Bioscience; PR Newswire)

Our Services

Orissa International provides consulting services to companies that want to develop a market entry strategy for Southeast Asia or implement their business expansion into the region. We have very strong domain knowledge of markets and industry sectors, and a business network of over 16,000 distributors, resellers, and system integrators, built through advising and guiding more than 5,000 companies with their market expansion into Singapore, Malaysia, Indonesia, Thailand, Vietnam and the Philippines over the last 25 years.